Logo image of PTCT

PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis

USA - NASDAQ:PTCT - US69366J2006 - Common Stock

65.95 USD
-0.87 (-1.3%)
Last: 10/17/2025, 8:00:01 PM
65.95 USD
0 (0%)
After Hours: 10/17/2025, 8:00:01 PM
Fundamental Rating

6

Taking everything into account, PTCT scores 6 out of 10 in our fundamental rating. PTCT was compared to 536 industry peers in the Biotechnology industry. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here. PTCT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes PTCT very considerable for growth investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year PTCT was profitable.
PTCT had a positive operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.
PTCT Yearly Net Income VS EBIT VS OCF VS FCFPTCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

PTCT has a better Return On Assets (23.89%) than 97.39% of its industry peers.
With an excellent Return On Invested Capital value of 34.54%, PTCT belongs to the best of the industry, outperforming 99.44% of the companies in the same industry.
Industry RankSector Rank
ROA 23.89%
ROE N/A
ROIC 34.54%
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTCT Yearly ROA, ROE, ROICPTCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

1.3 Margins

The Profit Margin of PTCT (35.65%) is better than 96.83% of its industry peers.
PTCT has a better Operating Margin (49.70%) than 99.44% of its industry peers.
PTCT has a better Gross Margin (97.09%) than 96.64% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
Industry RankSector Rank
OM 49.7%
PM (TTM) 35.65%
GM 97.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
PTCT Yearly Profit, Operating, Gross MarginsPTCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

6

2. Health

2.1 Basic Checks

PTCT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PTCT has been increased compared to 1 year ago.
PTCT has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PTCT is higher compared to a year ago.
PTCT Yearly Shares OutstandingPTCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PTCT Yearly Total Debt VS Total AssetsPTCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 2.13 indicates that PTCT is not a great score, but indicates only limited risk for bankruptcy at the moment.
PTCT has a better Altman-Z score (2.13) than 65.30% of its industry peers.
The Debt to FCF ratio of PTCT is 3.44, which is a good value as it means it would take PTCT, 3.44 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.44, PTCT belongs to the best of the industry, outperforming 93.66% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.44
Altman-Z 2.13
ROIC/WACC4.39
WACC7.87%
PTCT Yearly LT Debt VS Equity VS FCFPTCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B -1B 2B

2.3 Liquidity

PTCT has a Current Ratio of 3.62. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a Current ratio of 3.62. This is comparable to the rest of the industry: PTCT outperforms 42.35% of its industry peers.
PTCT has a Quick Ratio of 3.57. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT has a Quick ratio (3.57) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.57
PTCT Yearly Current Assets VS Current LiabilitesPTCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 226.85% over the past year.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 96.00%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%

3.2 Future

Based on estimates for the next years, PTCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.99% on average per year.
Based on estimates for the next years, PTCT will show a quite strong growth in Revenue. The Revenue will grow by 16.08% on average per year.
EPS Next Y226.6%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue Next Year114.65%
Revenue Next 2Y3.16%
Revenue Next 3Y9.8%
Revenue Next 5Y16.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PTCT Yearly Revenue VS EstimatesPTCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
PTCT Yearly EPS VS EstimatesPTCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 11.63 indicates a reasonable valuation of PTCT.
Compared to the rest of the industry, the Price/Earnings ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 97.39% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.40. PTCT is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 11.63
Fwd PE N/A
PTCT Price Earnings VS Forward Price EarningsPTCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PTCT indicates a rather cheap valuation: PTCT is cheaper than 98.32% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PTCT is valued cheaper than 98.88% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.51
EV/EBITDA 5.25
PTCT Per share dataPTCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PTCT's earnings are expected to grow with 24.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y18.49%
EPS Next 3Y24.02%

0

5. Dividend

5.1 Amount

PTCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PTC THERAPEUTICS INC

NASDAQ:PTCT (10/17/2025, 8:00:01 PM)

After market: 65.95 0 (0%)

65.95

-0.87 (-1.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)10-23 2025-10-23/amc
Inst Owners101.79%
Inst Owner Change-0.59%
Ins Owners0.7%
Ins Owner Change1.33%
Market Cap5.24B
Analysts78.26
Price Target67.93 (3%)
Short Float %9.42%
Short Ratio5.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2383.16%
Min EPS beat(2)23.33%
Max EPS beat(2)4742.99%
EPS beat(4)3
Avg EPS beat(4)1137.62%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)4
Avg EPS beat(8)542.76%
EPS beat(12)4
Avg EPS beat(12)346.13%
EPS beat(16)4
Avg EPS beat(16)252.2%
Revenue beat(2)2
Avg Revenue beat(2)293.95%
Min Revenue beat(2)2.58%
Max Revenue beat(2)585.33%
Revenue beat(4)3
Avg Revenue beat(4)147.39%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.39%
Revenue beat(12)7
Avg Revenue beat(12)50.4%
Revenue beat(16)10
Avg Revenue beat(16)39.02%
PT rev (1m)0%
PT rev (3m)6.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25.55%
EPS NY rev (1m)-0.74%
EPS NY rev (3m)27.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.88%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)-0.56%
Valuation
Industry RankSector Rank
PE 11.63
Fwd PE N/A
P/S 2.97
P/FCF 7.51
P/OCF 7.43
P/B N/A
P/tB N/A
EV/EBITDA 5.25
EPS(TTM)5.67
EY8.6%
EPS(NY)-3.58
Fwd EYN/A
FCF(TTM)8.78
FCFY13.31%
OCF(TTM)8.87
OCFY13.45%
SpS22.22
BVpS-2.6
TBVpS-5.45
PEG (NY)0.05
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 23.89%
ROE N/A
ROCE 43.72%
ROIC 34.54%
ROICexc 4029.4%
ROICexgc N/A
OM 49.7%
PM (TTM) 35.65%
GM 97.09%
FCFM 39.52%
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.44
Debt/EBITDA 2.36
Cap/Depr 26.13%
Cap/Sales 0.42%
Interest Coverage 203.36
Cash Conversion 77.86%
Profit Quality 110.85%
Current Ratio 3.62
Quick Ratio 3.57
Altman-Z 2.13
F-Score8
WACC7.87%
ROIC/WACC4.39
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)226.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y226.6%
EPS Next 2Y18.49%
EPS Next 3Y24.02%
EPS Next 5Y18.99%
Revenue 1Y (TTM)96%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%-4.19%
Revenue Next Year114.65%
Revenue Next 2Y3.16%
Revenue Next 3Y9.8%
Revenue Next 5Y16.08%
EBIT growth 1Y546.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year735.42%
EBIT Next 3Y50.48%
EBIT Next 5YN/A
FCF growth 1Y350.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y384.63%
OCF growth 3YN/A
OCF growth 5YN/A